表紙:子宮筋腫核出術の世界市場-2022-2029
市場調査レポート
商品コード
961510

子宮筋腫核出術の世界市場-2022-2029

Global Myomectomy Market - 2022-2029

出版日: | 発行: DataM Intelligence | ページ情報: 英文 190 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=152.41円
子宮筋腫核出術の世界市場-2022-2029
出版日: 2022年06月03日
発行: DataM Intelligence
ページ情報: 英文 190 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

市場力学

子宮筋腫核出術の世界市場の成長は、子宮筋腫の有病率の上昇と子宮疾患の診断および治療に対する需要の高まりに牽引されています。子宮筋腫および関連疾患に苦しむ患者数の増加、低侵襲手術の増加、安全かつ効果的な子宮筋腫摘出手術のための技術的に高度なデバイスの採用率の上昇が、市場の推進要因として期待されています。

子宮疾患の診断と治療に対する需要の高まりが市場成長の原動力となる

子宮筋腫は女性に最も多く見られる骨盤内腫瘍であり、全世界で21.4%の有病率で発生しています。女性の約20%~80%が50歳になるまでに子宮筋腫を発症します。子宮筋腫は40代から50代前半の女性によく見られます。アフリカ系アメリカ人女性の約80%が50歳までに子宮筋腫を発症するといわれています。女性の高齢化が進むと、ホルモンバランスの乱れや子宮の異常出血、月経不順などの婦人科系の問題を起こしやすくなるため、市場の成長を後押しし、世界の筋腫核出術市場の需要に拍車をかけているのです。2017年に発表された別の調査研究では、子宮筋腫を持つ約5,000人のイタリア人女性を対象に、実施された手術の95%に36~55歳の年齢層の女性が含まれていることが示されました。さらに、合併症の少なさや入院期間の短縮による低侵襲手術の増加も、市場の成長を後押しすると予想されます。また、質の高い効率的な治療を実現するためのロボット手術や腹腔鏡補助手術の増加など、技術的な進歩も子宮筋腫核出術市場の成長に寄与する可能性があります。

子宮筋腫に対する子宮筋腫核出術の増加による技術的に高度な製品の発売は、市場の成長を後押しすると思われます。腹腔鏡やロボット支援による子宮筋腫核出術のインダクションなどの技術的進歩により、子宮筋腫治療のための副作用がない、または最小限の切開不要の手術が示されています。腹腔鏡下子宮筋腫核出術は、開腹手術と比較して、出血量や合併症の発生率が少なく、入院期間も短く、通常の生活に戻るのも早いとされています。このように、子宮筋腫核出術にロボットを使用することは、従来の腹腔鏡手術(開腹手術)に比べていくつかの利点があり、生殖外科の分野でも広く受け入れられ、取り入れられています。

子宮筋腫核出術に伴う合併症が市場成長の妨げとなる

しかし、子宮筋腫核出術には、出血、感染、腸閉塞、癒着形成、腸・膀胱・卵管・尿管の損傷、創感染、創部剥離などが伴います。子宮筋腫核出術を受けた患者の約20~25%は、症状の再発のため、別の骨盤内手術、通常は子宮摘出術を必要とします。筋腫の再発は一般的で、特に多発性筋腫の患者さんではよく見られます。単発性筋腫の患者の再発率は27%であり、多発性筋腫の患者の再発率は59%です。子宮筋腫核出術を受ける患者には、これらのリスクについて術前にカウンセリングを行い、子宮筋腫核出術が不可能な場合があることを理解しておく必要があります。

COVID-19の影響度分析

COVID-19の大流行が子宮筋腫核出術の市場に与えるインパクトは大きいです。世界中でCOVID-19の症例が急増したため、ヘルスケアサービスはCOVID-19に苦しむ患者にリソースを振り向けた。パンデミック時の患者管理のためのガイドラインと推奨事項が提供されました。その結果、病院は緊急処置を優先し、子宮筋腫摘出手術などの選択的処置を遅らせたり延期したりすることになり、何カ月も手術を待つ患者の滞留を招きました。COVID-19による12週間の混乱のピーク時には、81.7%の良性手術を含む約2800万件の手術が遅延すると2020年のCovidSurg Collaborativeの調査では推定されています。条件が正常に戻ることで、子宮筋腫核出術は徐々に回復すると予想されます。

世界の子宮筋腫核出術市場レポートでは、約40以上の市場データ表、45以上の図、190ページの範囲でのアクセスを提供することになります。

目次

第1章 子宮筋腫核出術の世界市場の調査手法と範囲

  • 調査手法
  • 調査目的および調査範囲

第2章 子宮筋腫核出術の世界市場-市場の定義と概要

第3章 子宮摘出術の世界市場-エグゼクティブサマリー

  • タイプ別市場内訳
  • 製品別市場内訳
  • エンドユーザー別市場内訳
  • 地域別市場内訳

第4章 子宮筋腫核出術の世界市場-市場力学

  • 市場影響因子
    • 促進要因
      • 子宮疾患の診断と治療に対する需要の高まり
      • 低侵襲手術の台頭
    • 抑制要因
      • 子宮筋腫核出術に伴う合併症
    • ビジネスチャンス
    • 影響分析

第5章 子宮筋腫核出術の世界市場-産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 規制分析

第6章 子宮筋腫核出術の世界市場-COVID-19分析

  • COVID-19の市場分析
    • COVID-19以前の市場シナリオ
    • COVID-19の現在の市場シナリオ
    • COVID-19の後、または将来のシナリオ
  • COVID-19の中での価格ダイナミクス
  • 需要-供給製品
  • パンデミック時の市場に関連する政府の取り組み
  • メーカーの戦略的取り組み
  • まとめ

第7章 子宮筋腫核出術の世界市場-タイプ別

  • 腹腔鏡下
  • 腹腔鏡
  • ヒステロスコピー
  • ロボット

第8章 子宮筋腫核出術の世界市場-製品別

  • 腹腔鏡下パワーモルセレータ
  • 腹腔鏡下シーラー
  • ハーモニックメス
  • その他

第9章 子宮筋腫核出術の世界市場-エンドユーザー別

  • 病院・クリニック
  • 手術センター
  • その他

第10章 子宮筋腫核出術の世界市場-地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他の南米地域
  • アジア太平洋地域
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ地域

第11章 子宮筋腫核出術の世界市場- 競争情勢

  • 主な展開と戦略
  • 企業シェア分析
  • 製品ベンチマーク

第12章 子宮筋腫核出術の世界市場-企業プロファイル

  • Medtronic PLC
    • 企業概要
    • 製品ポートフォリオと説明
    • 主なハイライト
    • 財務概要
  • Stryker Corporation
  • ConMed Corporation
  • INSIGHTEC Ltd
  • CooperSurgical Inc.
  • Hologic Inc.
  • Intuitive Surgical Inc.
  • KARL STORZ SE & Co. KG
  • B Braun
  • Richard Wolf Medical Instruments

第13章 子宮筋腫核出術の世界市場-DataM

目次
Product Code: DMOT2667

Market Overview

The Global Myomectomy Market is expected to grow at a high CAGR of 9.1% during the forecasting period (2022-2029).

Myomectomy is a surgical procedure to remove uterine fibroids. These common non-cancerous growths in the uterus of women at their childbearing age, cause symptoms such as heavy bleeding during the menstrual cycle, increased menstrual cramping, pain in the pelvis or lower back, and swelling enlargement of the abdomen. Myomectomy preserves the chances of women getting pregnant.

Market Dynamics

The global myomectomy market growth is driven by the rising prevalence of uterine fibroids and the growing demand for the diagnosis and treatment of uterine disorders. The increasing number of patients suffering from uterine fibroids and associated conditions, the growing number of less invasive procedures, and the rising adoption of technologically advanced devices for safe and effective myomectomy procedures are the major factors expected to drive the market.

The growing demand for diagnosis and treatment of uterine disorder will drive the market growth

Uterine fibroids are the most common pelvic tumors in women, occurring globally with a prevalence of 21.4%. About 20% to 80% of women develop fibroids by the time they reach age 50. Fibroids are common in women in their 40s and early 50s. About 80% of African American women will develop fibroids by the age of 50. The increasing female aging population is propelling the growth of the market as the elderly population is more susceptible to gynecological problems, such as hormonal imbalance, abnormal uterine bleeding, and irregular menstrual cycle, which is fueling the demand for the global myomectomy market. Another research study published in 2017, which included approximately 5,000 Italian women with uterine fibroids, showed that 95% of the surgeries performed included women in the age group of 36-55 years. Additionally, a rise in the number of minimally invasive surgical procedures due to fewer complications and reduced hospital stay is anticipated to drive the growth of the market. Technological advancements, such as the rise in the number of robotic and laparoscopic-assisted surgeries to deliver quality and efficient treatment, may also contribute to the growth of the myomectomy market.

The launch of technologically advanced products due to the increasing number of myomectomy procedures for uterine fibroids is likely to boost the market growth. Technological advancements such as the introduction of laparoscopic or robotically assisted myomectomy procedures have shown incisionless surgery with no or minimal side effects for fibroids treatment. As compared to the open abdominal myomectomy surgery, with robotic myomectomy patient experience less blood loss with fewer complication rates, have a shorter hospital stay, and returns to normal activities more quickly. Thus, the use of robots for myomectomy surgery and their several advantages over conventional laparoscopy (open surgery), have been widely accepted and incorporated into the field of reproductive surgery.

The complications associated with myomectomy will hamper the growth of the market

However, myomectomy is associated with hemorrhage, infection, bowel obstruction, adhesion formation, damage to the bowel, bladder, fallopian tube, ureter, wound infection, and wound separation. About 20-25% of patients undergoing myomectomy require another pelvic operation, usually hysterectomy because of recurrence of symptoms. Recurrent myomas are common, especially in patients with multiple myomas. Patients with a solitary myoma have a 27% recurrence rate, and those with multiple myomas have a rate of 59%. Patients undergoing myomectomy should be counseled pre-operatively about these risks and must understand that myomectomy may not be possible.

COVID-19 Impact Analysis

The impact of the COVID-19 pandemic is significant on the myomectomy market. With the surge of COVID-19 cases across the world, healthcare services diverted their resources toward the patients suffering from COVID-19. Guidelines and recommendations were provided for the management of patients during the pandemic. This resulted in hospitals prioritizing emergency procedures and delaying or postponing elective procedures, such as myomectomy surgery, leading to a backlog of patients waiting for their surgeries for months. A CovidSurg Collaborative study, 2020, estimated that around 28 million operations would be delayed during the peak 12-week disruption due to COVID-19, including 81.7% benign surgeries. With conditions returning to normal, myomectomy procedures are expected to recover gradually.

Segment Analysis

The abdominal segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

The abdominal segment, also known as the open type, is considered the classic myomectomy surgery. This procedure is performed by making a small horizontal incision (or a vertical incision for a larger uterus) across the abdomen region of the body. With the rise in the number of patients with uterine fibroids, the demand for myomectomy procedures may also increase. Abdominal myomectomy is the highly performed and preferred type of treatment. A 2017 UK research study published on Gynecological Surgery, Springer Open, involving physician consultants, identifies that nearly 70% of them perform open myomectomy. The open type is preferred based on the size and location of fibroids. Hence, due to such activities across different countries, the number of procedures is expected to grow further over the forecast period.

Geographical Analysis

North America region holds the largest market share of the global myomectomy market

North America dominates the market for myomectomy and is expected to show a similar trend over the forecast period, owing to the rising prevalence of uterine fibroid. A 2018 article published in the American Journal of Obstetrics and Gynecology shows that the prevalence of uterine fibroids was found to be 10% in the United States, with higher occurring rates observed for black women and other ethnic or racial groups. Additionally, according to the World Economic Outlook 2021 by IMF, real GDP is projected to grow by 6.4% in the United States and 5% in Canada. These factors, coupled with high reimbursement rates and government initiatives, contribute to North America occupying the largest share of the overall myomectomy market.

The increased patient pool undergoing hormonal disorders and increasing prevalence of uterine cancer is the key growth driving factor for this regional uterine fibroid treatment market. For instance, in the USA, the prevalence of uterine fibroids was 60% at the age of 35, which increased to more than 80% by the age of 50 years among women.

Also, the adoption of minimally invasive and effective alternatives to open surgeries and technological advancements in devices with an increase in regulatory approvals and favorable reimbursement policies are expected to boost the growth of the myomectomy market in this region.

Competitive Landscape

The myomectomy market is a moderately competitive presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Medtronic PLC, Stryker Corporation, ConMed Corporation, INSIGHTEC Ltd, CooperSurgical Inc., Hologic Inc., Intuitive Surgical Inc., KARL STORZ SE & Co. KG, B Braun, Richard Wolf Medical Instruments among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the Myomectomy Market globally. For instance, in August 2020, Hologic Inc. announced the acquisition of Acessa Health Inc., a privately held company focused on minimally invasive therapies for fibroids. This acquisition is anticipated to strengthen Hologic's fibroid treatment product portfolio.

Medtronic plc

Overview:

Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiovascular Portfolio, Neuroscience Portfolio, Medical-Surgical Portfolio, and Diabetes Operating Unit.

Product Portfolio:

Veriset Hemostatic Patch: The Veriset patch is designed to address the unmet need for a simple to use, fast, and highly effective hemostatic patch. Medtronic launched the Veriset patch. It is designed to help to achieve hemostasis quickly and consistently, in ~1 minute.

Why Purchase the Report?

Visualize the composition of the global myomectomy market segmentation by type, product, end-user, and region highlighting the key commercial assets and players.

Identify commercial opportunities in the global myomectomy market by analyzing trends and co-development deals.

Excel data sheet with thousands of data points of global myomectomy market-level 4/5 segmentation.

PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.

Product mapping in excel for the key product of all major market players

The global myomectomy market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 190 pages.

Table of Contents

1. Global Myomectomy Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Global Myomectomy Market -Market Definition and Overview

3. Global Myomectomy Market - Executive Summary

  • 3.1. Market Snippet By Type
  • 3.2. Market snippet By Product
  • 3.3. Market Snippet By End User
  • 3.4. Market Snippet by Region

4. Global Myomectomy Market-Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. The growing demand for diagnosis and treatment of the uterine disorder
      • 4.1.1.2. Rise in Minimally Invasive Procedures
    • 4.1.2. Restraints:
      • 4.1.2.1. The complications associated with myomectomy
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Global Myomectomy Market - Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Regulatory Analysis

6. Global Myomectomy Market - COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Product
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. Global Myomectomy Market - By Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type Segment
    • 7.1.2. Market Attractiveness Index, By Type Segment
  • 7.2. Laparoscopic*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Abdominal
  • 7.4. Hysteroscopic
  • 7.5. Robotic

8. Global Myomectomy Market - By Product

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 8.1.2. Market Attractiveness Index, By Product
  • 8.2. Laparoscopic Power Morcellators*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Laparoscopic Sealer
  • 8.4. Harmonic Scalpel
  • 8.5. Others

9. Global Myomectomy Market - By End User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 9.1.2. Market Attractiveness Index, By End User Segment
  • 9.2. Hospitals & Clinics *
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Surgical Centers
  • 9.4. Other

10. Global Myomectomy Market - By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. The U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

11. Global Myomectomy Market - Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Product Benchmarking

12. Global Myomectomy Market - Company Profiles

  • 12.1. Medtronic PLC*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Stryker Corporation
  • 12.3. ConMed Corporation
  • 12.4. INSIGHTEC Ltd
  • 12.5. CooperSurgical Inc.
  • 12.6. Hologic Inc.
  • 12.7. Intuitive Surgical Inc.
  • 12.8. KARL STORZ SE & Co. KG
  • 12.9. B Braun
  • 12.10. Richard Wolf Medical Instruments

LIST NOT EXHAUSTIVE

13. Global Myomectomy Market - DataM

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us